Intellia Therapeutics

Gene Editing Therapeutics Could Hit the Market in 2023
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Flag link:
Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach
Intellia Seeks to Broaden Gene Editing’s Potential with Full-Spectrum Approach
BioSpace
gene editing
Intellia Therapeutics
Flag link:
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
Investors Business Daily
Intellia Therapeutics
CRISPR
FDA
Flag link:
Novartis Drops SCD Gene Therapy Program with Intellia
Novartis Drops SCD Gene Therapy Program with Intellia
BioSpace
Novartis
sickle cell disease
Intellia Therapeutics
CRISPR
gene editing
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
10 Massachusetts Biopharma Companies Hiring Now
10 Massachusetts Biopharma Companies Hiring Now
BioSpace
Massachusetts
hirings
AbbVie
Moderna Therapeutics
CSL
Intellia Therapeutics
Schrödinger
Visterra
Alloy Therapeutics
Werewolf Therapeutics
Sherlock Biosciences
Flag link:
The gloom deepens for biopharma stocks
The gloom deepens for biopharma stocks
EP Vantage
biopharma stocks
AbbVie
Alnylam
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eisai
Eli Lilly
GSK
Intellia Therapeutics
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Flag link:
Intellia's Latest Data Indicate Full Potential of CRISPR
Intellia's Latest Data Indicate Full Potential of CRISPR
BioSpace
Intellia Therapeutics
ATTR amyloidosis
hereditary angiodema
CRISPR
Flag link:
Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential
Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential
Fierce Biotech
Intellia Therapeutics
gene editing
NTLA-2001
ATTR amyloidosis
clinical trials
Regeneron
Flag link:
Big Pharma partnerships, record $22.7B investment raise profile of regenerative medicine in 2021
Big Pharma partnerships, record $22.7B investment raise profile of regenerative medicine in 2021
Fierce Biotech
regenerative medicine
gene editing
gene therapy
Big Pharma
Intellia Therapeutics
Flag link:
Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch
Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch
Fierce Biotech
Intellia Therapeutics
CRISPR
FDA
cell therapy
orphan drugs
Flag link:
Intellia presses forward with new results for pioneering CRISPR drug
Intellia presses forward with new results for pioneering CRISPR drug
BioPharma Dive
Intellia Therapeutics
CRISPR
transthyretin amyloidosis
Flag link:
Intellia follows CRISPR peers with deal to explore 'natural killer' cell therapy
Intellia follows CRISPR peers with deal to explore 'natural killer' cell therapy
BioPharma Dive
Intellia Therapeutics
ONK Therapeutics
natural killer cell therapy
immunotherapy
Flag link:
Intellia’s Rewrite Therapeutics buyout brings new precision to gene editing
Intellia’s Rewrite Therapeutics buyout brings new precision to gene editing
MedCity News
Intellia Therapeutics
Rewrite Therapeutics
gene editing
M&A
Flag link:
Intellia doses first patient as hereditary angioedema gene editing therapy lands in clinic
Intellia doses first patient as hereditary angioedema gene editing therapy lands in clinic
Fierce Biotech
Intellia Therapeutics
HAE
clinical trials
NTLA-2002
Flag link:
Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report
Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report
Fierce Biotech
Intellia Therapeutics
LogicBio Therapeutics
gene editing
NTLA-2001
ATTR amyloidosis
Flag link:
Intellia looks to eye diseases in latest deal
Intellia looks to eye diseases in latest deal
BioPharma Dive
Intellia Therapeutics
gene editing
eye disease
Flag link:
Jennifer Doudna Reacts to Intellia CRISPR Breakthrough, Outlines Challenges
Jennifer Doudna Reacts to Intellia CRISPR Breakthrough, Outlines Challenges
BioSpace
Jennifer Doudna
CRISPR
Intellia Therapeutics
Flag link:
3 Biotech Stocks With Big Catalysts in June
3 Biotech Stocks With Big Catalysts in June
Motley Fool
Corbus Pharmaceuticals
lenabasum
clinical trials
Gemini Therapeutics
age-related macular degeneration
Intellia Therapeutics
hATTR-pn
Flag link:
8 key clinical trials to watch for the rest of 2021
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:

Pages